Investigating liver health in patients with Anorexia Nervosa
Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa
This study is trying to see how common liver problems are in people with Anorexia Nervosa by using a special scan and blood tests while they are in the hospital.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Trial ID | NCT05861375 on ClinicalTrials.gov |
What this trial studies
The Liver Biomarkers in Anorexia Nervosa (LIBAN) study aims to assess the prevalence of liver fibrosis in patients diagnosed with Anorexia Nervosa. This observational study will utilize non-invasive methods, specifically the Fibroscan®, to evaluate liver health in an inpatient population. Additionally, liver blood markers will be analyzed to provide further insights into the hepatic condition of these patients. The study focuses on individuals admitted to the endocrinology, diabetology, and nutrition department of Nantes University Hospital.
Who should consider this trial
Good fit: Ideal candidates include individuals over 15 years old with a diagnosis of Anorexia Nervosa who are currently hospitalized.
Not a fit: Patients with chronic active viral hepatitis, hemochromatosis, or those with excessive alcohol consumption may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of liver health in Anorexia Nervosa patients, leading to better management and treatment strategies.
How similar studies have performed: While the approach of using Fibroscan® is established, the specific focus on liver biomarkers in Anorexia Nervosa is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria : * Patient over 15 years old * Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) * Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital. Exclusion Criteria : * Chronic active viral hepatitis * Hemochromatosis * Other genetic, autoimmune, toxic or drug-induced hepatitis * Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months * Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)
Where this trial is running
Nantes, Loire-Atlantique
- Nantes University Hospital — Nantes, Loire-Atlantique, France (Recruiting)
Study contacts
- Principal investigator: Sarra SMATI-GRANGEON, PH — Nantes University Hospital
- Study coordinator: Sarra SMATI-GRANGEON, PH
- Email: sarra.grangeon@chu-nantes.fr
- Phone: 33 2.53.48.27.01
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.